OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0001661181

Organogenesis Holdings Inc. (ORGO)

Organogenesis Holdings Inc. (CIK 0001661181, ticker ORGO) reported revenue of $564.17 million ($564,169,000) for FY2025 (2025-01-01 to 2025-12-31) and net income of $37.03 million ($37,032,000) for FY2025 (2025-01-01 to 2025-12-31), as filed in its 10-K filed 2026-02-26 (accession 0001193125-26-076730).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0001661181
TickersORGO (Nasdaq)
EINnot in EDGAR (or not a valid EIN)
SIC industry code2834 Pharmaceutical Preparations
State or country of incorporationDE
Fiscal year endDecember 31
Filer categoryAccelerated filer
Entity typeoperating
Olympus entity IDorg_4tx3pg9xxr67q6jt4gp8cy6q9p
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$564,169,000FY20252025-01-01 to 2025-12-3110-K2026-02-260001193125-26-076730Revenues
Net income$37,032,000FY20252025-01-01 to 2025-12-3110-K2026-02-260001193125-26-076730NetIncomeLoss
Total assets$598,730,000FY2025as of 2025-12-3110-K2026-02-260001193125-26-076730Assets
Total liabilities$164,812,000FY2025as of 2025-12-3110-K2026-02-260001193125-26-076730Liabilities
Stockholders' equity$300,129,000FY2025as of 2025-12-3110-K2026-02-260001193125-26-076730StockholdersEquity
Operating cash flow-$10,309,000FY20252025-01-01 to 2025-12-3110-K2026-02-260001193125-26-076730NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share$0.15 per shareFY20252025-01-01 to 2025-12-3110-K2026-02-260001193125-26-076730EarningsPerShareDiluted
Shares outstanding128,640,671 sharesFY2025as of 2026-02-2310-K2026-02-260001193125-26-076730EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2016-2025, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20252025-01-01 to 2025-12-31$564,169,00010-K2026-02-260001193125-26-076730
RevenueFY20242024-01-01 to 2024-12-31$482,043,00010-K2026-02-260001193125-26-076730
RevenueFY20232023-01-01 to 2023-12-31$433,140,00010-K2026-02-260001193125-26-076730
RevenueFY20222022-01-01 to 2022-12-31$450,893,00010-K2025-02-270000950170-25-029137
RevenueFY20212021-01-01 to 2021-12-31$467,359,00010-K2024-02-290000950170-24-023150
RevenueFY20202020-01-01 to 2020-12-31$338,298,00010-K2023-03-010000950170-23-005585
RevenueFY20192019-01-01 to 2019-12-31$260,981,00010-K2022-03-010001193125-22-061686
RevenueFY20182018-01-01 to 2018-12-31$193,449,00010-K2021-03-160001193125-21-082849
RevenueFY20172017-01-01 to 2017-12-31$198,508,00010-K2020-03-090001193125-20-067198
RevenueFY20162016-01-01 to 2016-12-31$138,732,00010-K2019-03-180001193125-19-078332
Net incomeFY20252025-01-01 to 2025-12-31$37,032,00010-K2026-02-260001193125-26-076730
Net incomeFY20242024-01-01 to 2024-12-31$861,00010-K2026-02-260001193125-26-076730
Net incomeFY20232023-01-01 to 2023-12-31$4,945,00010-K2026-02-260001193125-26-076730
Net incomeFY20222022-01-01 to 2022-12-31$15,532,00010-K2025-02-270000950170-25-029137
Net incomeFY20212021-01-01 to 2021-12-31$94,202,00010-K2024-02-290000950170-24-023150
Net incomeFY20202020-01-01 to 2020-12-31$17,234,00010-K2023-03-010000950170-23-005585
Net incomeFY20192019-01-01 to 2019-12-31-$38,709,00010-K2022-03-010001193125-22-061686
Net incomeFY20182018-01-01 to 2018-12-31-$64,831,00010-K2021-03-160001193125-21-082849
Net incomeFY20172017-01-01 to 2017-12-31-$8,388,00010-K2020-03-090001193125-20-067198
Net incomeFY20162016-01-01 to 2016-12-31-$16,987,00010-K2019-03-180001193125-19-078332
  • Revenue for FY2021 was restated: first reported as $468,059,000 (accession 0001193125-22-061686, filed 2022-03-01).
  • Net income for FY2021 was restated: first reported as $94,902,000 (accession 0001193125-22-061686, filed 2022-03-01).
  • Net income for FY2020 was restated: first reported as $17,949,000 (accession 0001193125-21-082849, filed 2021-03-16).
  • Net income for FY2019 was restated: first reported as -$40,454,000 (accession 0001193125-20-067198, filed 2020-03-09).
  • Net income for FY2017 was restated: first reported as -$2,093,913 (accession 0001558370-18-002068, filed 2018-03-14).
  • Net income for FY2016 was restated: first reported as -$208,698 (accession 0001047469-17-002096, filed 2017-03-28).

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-Q2026-08-062026-06-300001193125-26-338049orgo-20260630.htm
10-Q2026-05-072026-03-310001661181-26-000008orgo-20260331.htm
10-K2026-02-262025-12-310001193125-26-076730orgo-20251231.htm
10-Q2025-11-062025-09-300001193125-25-269697orgo-20250930.htm
10-Q2025-08-072025-06-300000950170-25-105048orgo-20250630.htm
10-Q2025-05-082025-03-310000950170-25-066962orgo-20250331.htm
10-K/A2025-04-292024-12-310001193125-25-104050d574678d10ka.htm
10-K2025-02-272024-12-310000950170-25-029137orgo-20241231.htm
10-Q2024-11-122024-09-300000950170-24-125431orgo-20240930.htm
10-Q2024-08-082024-06-300000950170-24-094009orgo-20240630.htm
10-Q2024-05-092024-03-310000950170-24-057050orgo-20240331.htm
10-K2024-02-292023-12-310000950170-24-023150orgo-20231231.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0001661181published by the sourcedata.sec.gov/submissions/CIK0001661181.json2026-10-21

Former names

NameFromTo
Avista Healthcare Public Acquisition Corp.2015-12-182018-12-10

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0001661181.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0001661181.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001661181" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001661181/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001661181/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"1661181"}

On SEC EDGAR

About this data